Optimization of approaches to the treatment of metastatic colorectal cancer wild-type gene KRAS

Abstract

The results of the literature review of drug use for the treatment of metastatic colorectal cancer (mCRC) are presented. Analysis of the data showed that cetuximab (Erbitux) and panitumumab (Vectibix) are effective drugs for mCRC patients with KRAS wild-type in the first-line therapy, and the combination of standard chemotherapy regimen FOLFOX in combination with targeted therapy cetuximab (Erbitux) is the most optimal medical technology as compared with other combinations of chemotherapy and targeted drugs.